David Coman
CEO & Director
David Coman joined Science 37 in November 2019 as Chief Executive Officer. He came to Science 37 from ERT, where he served as Chief Strategy Officer. As the leader of ERT’s data and analytics business, David reimagined the way the pharmaceutical industry looks at performance and risk management for clinical trials. Prior to ERT, David was Chief Marketing Officer of IQVIA, formerly Quintiles, where he was also the founder of its Digital Patient business and pioneered some of the industry’s first decentralized clinical trials. Prior to Quintiles, David was the Chief Marketing Officer at Dendrite International, which is also now owned by IQVIA. Earlier in his career, David held a variety of marketing leadership roles in telecommunications, including AOL Local & Long Distance (Talk America), Excel Communications, and Aerial Communications. David earned a B.A. in advertising from Michigan State University and an MBA in marketing, entrepreneurship, and finance from the Kellogg Graduate School of Management at Northwestern University.
Robert Faulkner
Chairman
Rob has been a Managing Director at Redmile Group, LLC, a health care-focused investment firm, since February 2008. Prior to Redmile, Rob was a sell-side equity analyst for 16 years, from 1992 to 2008, including at Hambrecht & Quist (now JPMorgan), Thomas Weisel Partners (now Stifel Financial Corp.) and SG Warburg & Co. (now UBS). He has also served as a director of MedAvail Holdings, Inc. since November 2020. Rob received a Bachelor of Arts in Government in 1984 from Harvard College and a Master of Business Administration from the Tuck School of Business at Dartmouth College in 1990.
Chairman of the Board
Bhooshitha B. De Silva
Director
Bhooshitha B. De Silva has been Senior Vice President, Global Head of Corporate Development and Strategy, at Pharmaceutical Product Development, a global contract research organization providing drug development, laboratory and lifecycle management services, since 2014. Prior to that, he served as Vice President, Corporate Development and Head of International, of Optimer, a materials research, development, and testing laboratory, from 2011 to 2014 and Vice President, Head of Business Development and Strategy, of Pfizer, Inc. (NYSE: PFE), a pharmaceutical corporation, from 2000 to 2011. Bhooshitha received a Master of Engineering degree from Imperial College London in 1995, a Master of Science degree in Economics from the London School of Economics in 1997 and a Master of Science degree in Management Science from Stanford University in 2000.
Adam Goulburn
Director
Adam Goulburn has been a Partner at Lux Capital, a venture capital firm since November 2011. Adam has also served and serves on the boards of directors of various companies in the healthcare industry, including AllStripes, Cajal Neuroscience, Eikon Therapeutics, Kallyope, Mahana Therapeutics, Plexium, Vesta Healthcare, VNV Newco and Rivet Health. During Adam’s directorship at these companies, he has served on numerous Audit Committees. Adam received a Bachelor of Commerce / Bachelor of Science degree in Commerce and Science from the University of New South Wales in 2005 and a Doctor of Philosophy degree from Monash University in 2010.
John W. Hubbard
Director
Prior to joining Science 37, John was the President and Chief Executive Officer of Bioclinica, Inc., an integrated clinical life science solutions provider, from 2015 to 2018, during which he also served as member of Bioclinica’s board of directors and audit committee. John has also served and serves on the boards of directors of various companies, including Agile Therapeutics, Inc. (NASDAQ: AGRX) since October 2014, Signant Health (formerly CRF Health and Bracket) since July 2018, where he also serves as the Chairman of the Board of Directors, and Advarra, Inc. since July 2019, where he also serves as independent director. He currently serves as Healthcare Strategic Advisory Board Member of Genstar Capital, a leading middle-market private equity firm, since 2018. John has also served as Chairman of the Science & Technology Committee of Agile Therapeutics, from June 2015 to June 2020, where he currently serves as Chairman of the Nominating and Governance Committee since June 2020, and member of the Audit Committee since January 2015 and the Finance Committee since June 2015. John received a Bachelor of Science degree from Santa Clara University and a Doctor of Philosophy degree from the University of Tennessee.
Emily Rollins
Director
Ms. Rollins has served in various positions at Deloitte & Touche LLP (“Deloitte”) beginning in 1992, including as an Audit and Assurance Partner from 2006 to 2020. At Deloitte, Ms. Rollins served technology and media companies and guided hundreds of clients through complex audit and reporting processes. Ms. Rollins also served in positions of increasing responsibility, including leadership roles in Deloitte’s U.S. Technology, Media, and Telecommunications industry group, Audit Innovation and Transformation, and Diversity and Inclusion. She led firm-wide initiatives to recruit, develop and retain women and diverse professionals as well as transform and modernize Deloitte’s audit platform. Ms. Rollins currently serves on the boards of directors of Dolby Laboratories, Inc. (NYSE:DLB) and Xometry, Inc. (Nasdaq: XMTR). In addition, Ms. Rollins serves on the boards of several privately held companies, as well as non-profit entities and associations. Ms. Rollins is a Certified Public Accountant and holds a B.A. degree in Accounting and International Relations from Claremont McKenna College. We believe Ms. Rollins is qualified to serve on our Board based on her extensive experience and service as a director at numerous companies.
Neil Tiwari
Director
Neil has served as a Partner of Private Healthcare Ventures at Magnetar Capital, a global hedge fund with over $14 billion of assets under management, based in Evanston, IL, since May 2021. Prior to this role, Neil served as Managing Director of dRx Capital, the digital health venture arm for Novartis, a global healthcare company based in Switzerland, from April 2019 to May 2021. Previously, Neil served as Principal of dRx Capital from September 2017 to April 2019 and served in senior product development roles from April 2015 to September 2017. He has served on the boards of directors of multiple companies, where he also served as a member of the Compensation and Mergers and Acquisitions Committees. Neil received a Bachelor of Science degree in Biomedical Engineering from Northwestern University in 2008, a Master of Science degree in Biomedical Engineering from Northwestern University in 2008 and a Master of Business Administration degree from the Haas School of Business at the University of California, Berkeley in 2018.